Opinion|Videos|May 20, 2024
Utilization of Neuroimaging in Alzheimer’s Disease
Key opinion leaders emphasize the importance of neuroimaging in Alzheimer's disease, as it can rule out different diseases and diagnose microbleeds, while also discussing which biomarkers, histopathological features, and imaging characteristics are associated with different stages of the disease, exploring whether these tools can provide insights into the true onset of Alzheimer's disease.
Advertisement
Episodes in this series
- Describe the use of neuroimaging in AD.
- Which imaging features are associated with different stages of Alzheimer’s disease?
Can they tell us when Alzheimer’s disease really starts?
Advertisement
Related to this article
In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5